Impact of cardiovascular (CV) risk factors in participants with T2D during the first 6-months of observational period were examined in this 3 year prospective study (LANDMARC; CTRI/2017/05/008452). CV risk factors (rate of hypertension, dyslipidemia, albuminuria, and family history of premature coronary disease) at baseline (V1) and 6 months (Visit 2 [V2]) were assessed and compared between subgroups. Overall, >50% of the participants who had A1C data available, had CV risks at both V1 (2385/4479; 53.2%) and V2 (2422/4479; 54.1%). More than half of the participants with obesity (BMI ≥25 kg/m2) had CV risks at V1 (2305/4150; 55.5%) and V2 (2340/4150; 56.4%). On comparing the insulin (N=1548) vs. insulin naïve (N=4688) subgroups, a higher proportion of participants on insulin had CV risks than those who were insulin naïve (V1: 60.1% vs. 50.1%; V2: 60.8% vs. 50.9%). At V2, hypertension and dyslipidemia were more predominant in those with BMI ≥23 kg/m2 than <23 kg/m2, with A1C ≥ 7% than <7%, and in men than women (Table). In India, CV risks may be increased in people with T2D who are overweight, have suboptimal glycemic control, or are men. The real-world trend of CV risks may offer insights and direction for risk factor modifications and treatment adjustments.
R. Ghosh: Employee; Self; Sanofi. A.K. Das: Advisory Panel; Self; Novo Nordisk A/S, Sanofi. S. Joshi: Advisory Panel; Self; Novo Nordisk A/S, Roche Pharma, Sanofi. A. Mithal: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson, Lilly Diabetes, Novo Nordisk A/S. K. Kumar: None. S. Kalra: Advisory Panel; Self; Eli Lilly and Company. Speaker’s Bureau; Self; Novo Nordisk A/S, Sanofi-Aventis. A. Unnikrishnan: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker’s Bureau; Self; Eli Lilly and Company, Ipca Laboratories, Merck Sharp & Dohme Corp., Novartis AG. H. Thacker: None. B. Sethi: None. S. Mohanasundaram: Employee; Self; Sanofi. S.K. Menon: None. A. Nair: Employee; Self; Sanofi. N. Rais: None. S. Wangnoo: None. S. Chowdhury: Advisory Panel; Self; Novo Nordisk A/S. A.H. Zargar: None.
Sanofi India Limited